Argentum And Eli Lilly Settle Patent Dispute Over CIALIS

Published: Aug 23, 2017

NEW YORK, Aug. 22, 2017 /PRNewswire/ -- Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement and license agreement with Eli Lilly and Company related to Argentum's generic version of CIALISĀ® (tadalifil).

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

The agreement generally provides that Argentum may commence marketing its generic product no earlier than September 27, 2018. The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.

CIALISĀ® is a registered trademark of Eli Lilly and Company.

View original content with multimedia:http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-and-eli-lilly-settle-patent-dispute-over-cialis-300508183.html

SOURCE Argentum Pharmaceuticals LLC

Back to news